Skip to content
BMarker
TransactionsPerformanceSharingStocks & ETFsDemoPricingAPI Docs
Open app
Menu
TransactionsPerformanceSharingStocks & ETFsDemoPricingAPI Docs
Open app
  • CCL vs MRNA✓SelectedUSD · MRNACCL vs MRNA performance historyLatest closeAs of-4.83%11/19
Stock and ETF performance explorer

CCL vs MRNA

vs
1w1mo3mo6mo1y3y5y10yallcustom
Portfolio return
+93.2%
MRNA return
+159.5%
Excess return
-66.3%
Maximum drawdown
-42.3%

Performance

Returns, benchmark comparison, and relative performance.

Performance by timeframe

Returns for 3y.

Portfolio and benchmark returns by period
PeriodPortfolioMRNAExcessAlpha
1D-4.8%+1.3%-6.1%-4.9%
7D-6.0%-13.8%+7.8%-5.4%
30D+2.4%-17.7%+20.1%+3.3%
3M+3.8%+14.3%-10.5%+2.8%
6M+16.6%+336.0%-319.4%-0.3%
YTD-7.8%+575.9%-583.7%-28.5%
1Y+8.0%+724.4%-716.4%-19.3%
All+93.2%+159.5%-66.3%+56.0%

Cumulative growth

Daily Returns

Daily percentage return beside MRNA.

Daily Out/Under-Performance

Portfolio return minus MRNA return. Positive bars indicate outperformance.

Daily Alpha

Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.

Cumulative Out/Under-Performance

Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.

Cumulative Alpha

Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.

Updating return analytics…

3y analysis · Full analysis span regression · 6 months rolling